Effects of continued tobacco use during treatment of lung cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 10, 2010, Pages 1569-1575

  Waller, Lynsay L ^a,b   Weaver, Kathryn E ^b,c   Petty, W Jeffrey ^a,b   Miller, Antonius A ^a,b  

^a Section on Hematology and Oncology   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

lung cancer; smoking cessation; tobacco; toxicities; treatment

Indexed keywords

AMFEBUTAMONE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; IRINOTECAN; VARENICLINE; VINCRISTINE;

ABSTINENCE; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER THERAPY; CIGARETTE SMOKING; DRUG DOSE ESCALATION; DRUG METABOLISM; HUMAN; INTERVENTION STUDY; LUNG CANCER; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHYSICIAN; PRIMARY TUMOR; PROGNOSIS; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; STRESS; TOBACCO DEPENDENCE;

DRUG INTERACTIONS; HUMANS; LUNG NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SMOKING; SMOKING CESSATION; TOBACCO; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 77958050047     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.140     Document Type: Review

References (49)

1. Parkin DM, Pisani P, Lopez AD, Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int. J. Cancer 59(4), 494-504 (1994).
2. Sanderson Cox L, Sloan JA, Patten CA et al. Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancer. Psychooncology 11(6), 472-478 (2002).
3. Garces YI, Yang P, Parkinson J et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 126(6), 1733-1741 (2004). (Pubitemid 39643973)
4. Schnoll RA, James C, Malstrom M et al. Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann. Behav. Med. 25(3), 214-222 (2003).
5. Cooley ME, Sarna L, Brown JK et al. Tobacco use in women with lung cancer. Ann. Behav. Med. 33(3), 242-250 (2007).
6. Simmons VN, Litvin EB, Patel RD et al. Patient-provider communication and perspectives on smoking cessation and relapse in the oncology setting. Patient Educ. Couns. 77(3), 398-403 (2009).
7. Cooley ME, Sarna L, Kotlerman J et al. Smoking cessation is challenging even for patients recovering from lung cancer surgery with curative intent. Lung Cancer 66(2), 218-225 (2009).
8. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer 44(3), 287-293 (2004).
9. Samant RS, Tucker TL. Analysis of cigarette smoking habits of cancer patients referred to the Northeastern Ontario Regional Cancer Centre. J. Cancer Educ. 18(3), 157-160 (2003).
10. Walker MS, Vidrine DJ, Gritz ER et al. Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 15(12), 2370-2377 (2006).
11. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob. Res. 4(2), 149-159 (2002).
12. Bluman LG, Mosca L, Newman N, Simon DG. Preoperative smoking habits and postoperative pulmonary complications. Chest 113(4), 883-889 (1998).
13. Rugg T, Saunders MI, Dische S. Smoking and mucosal reactions to radiotherapy. Br. J. Radiol. 63(751), 554-556 (1990).
14. Møller AM, Villebro N, Pedersen T, Tønnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 359(9301), 114-117 (2002).
15. Sørensen LT, Jørgensen S, Petersen LJ et al. Acute effects of nicotine and smoking on blood flow, tissue oxygen, and aerobe metabolism of the skin and subcutis. J. Surg. Res. 152(2), 224-230 (2009).
16. Jensen JA, Goodson WH, Hopf HW, Hunt TK. Cigarette smoking decreases tissue oxygen. Arch. Surg. 126(9), 1131-1134 (1991).
17. Nakagawa M, Tanaka H, Tsukuma H, Kishi Y. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. Chest 120(3), 705-710 (2001).
18. Barrera R, Shi W, Amar D et al. Smoking and timing of cessation: impact on pulmonary complications after thoracotomy. Chest 127(6), 1977-1983 (2005).
19. van der Bol JM, Mathijssen RH, Loos WJ et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol. 25(19), 2719-2726 (2007).
20. Kanai M, Morita S, Matsumoto S et al. A history of smoking is inversely correlated with incidence of gemcitabine-induced neutropenia. Ann. Oncol. 20(8), 1397-1401 (2009).
21. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
22. Hughes AN, O'Brien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J. Clin. Oncol. 27(8), 1220-1226 (2009).
23. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 12(7 Pt 1), 2166-2171 (2006).
24. Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J. Clin. Oncol. 25(21), 3055-3060 (2007).
25. Kroon LA. Drug interactions with smoking. Am. J. Health Syst. Pharm. 64(18), 1917-1921 (2007).
26. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet. 36(6), 425-438 (1999).
27. Santos A, Zanetta S, Cresteil T et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. 6(5), 2012-2020 (2000).
28. Zhang J, Kamdar O, Le W, Rosen GD, Upadhyay D. Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer. Am. J. Respir. Cell Mol. Biol. 40(2), 135-146 (2009).
29. Dasgupta P, Rizwani W, Pillai S et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int. J. Cancer 124(1), 36-45 (2009).
30. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006). (Pubitemid 44917502)
31. Shin VY, Wu WK, Chu KM et al. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol. Cancer Res. 3(11), 607-615 (2005).
32. Conklin BS, Zhao W, Zhong DS, Chen C. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am. J. Pathol. 160(2), 413-418 (2002).
33. Kanda Y, Watanabe Y. Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. Life Sci. 80(15), 1409-1414 (2007). (Pubitemid 46367068)
34. Johnston-Early A, Cohen MH, Minna JD et al. Smoking abstinence and small cell lung cancer survival. An association. JAMA 244(19), 2175-2179 (1980).
35. Videtic GM, Stitt LW, Dar AR et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J. Clin. Oncol. 21(8), 1544-1549 (2003).
36. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. Br. Med. J. 340, b5569 (2010).
37. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 125(1), 27-37 (2004).
38. Richardson GE, Tucker MA, Venzon DJ et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann. Int. Med. 119(5), 383-390 (1993).
39. Kawahara M, Ushijima S, Kamimori T et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br. J. Cancer 78(3), 409-412 (1998).
40. Tucker MA, Murray N, Shaw EG et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J. Natl Cancer Inst. 89(23), 1782-1788 (1997).
41. Baser S, Shannon VR, Eapen GA et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 130(6), 1784-1790 (2006).
42. Daniel M, Keefe FJ, Lyna P et al. Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J. Pain 10(3), 323-328 (2009).
43. Myrdal G, Valtysdottir S, Lambe M, Stahle E. Quality of life following lung cancer surgery. Thorax 58(3), 194-197 (2003).
44. Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir. Care 45(10), 1196-1199 (2000).
45. DiClemente CC, Delahanty JC, Fiedler RM. The journey to the end of smoking: a personal and population perspective. Am. J. Prev. Med. 38(3 Suppl.), S418-S428 (2010).
46. Gonzales D, Rennard SI, Nides M et al. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1), 47-55 (2006).
47. Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296(1), 56-63 (2006).
48. US FDA: Information for healthcare professionals: Varenicline (marketed as Chantix) www.fda.gov/Drugs/DrugSafety/PostMarketDrugSafetyInformationfor PatientsandProviders/ucm124818.htm
49. US Department of Health and Human Services Public Health Service. Helping smokers quit: a guide for clinicians (2008) www.ahrq.gov/clinic/tobacco/ clinhlpsmksqt.pdf